Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX04CA)

• Drug Name: VB-111 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Malignant glioma	2A00.0	Phase 3	[1]
Ovarian cancer	2C73	Phase 3	[2]
Recurrent glioblastoma	2A00.00	Phase 3	[2]
Glioblastoma multiforme	2A00.0	Phase 2	[3]

• Cross-matching ID: TTD Drug ID: DMX04CA

Molecule-Related Drug Atlas

Drug(s) Targeting Apoptosis mediating surface antigen FAS (FAS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DE-098	DM5XT3G	Rheumatoid arthritis	FA20	Phase 2	[5]
APG-101	DM0FXMZ	Cerebrovascular ischaemia	8B1Z	Phase 2	[6]
APO-010	DMPJBCR	Multiple myeloma	2A83	Phase 1	[7]
2-aminophenoxazine-3-one	DMBVGAO	T-cell leukaemia	2A90	Investigative	[8]
F61F12	DMD7HO8	Solid tumour/cancer	2A00-2F9Z	Investigative	[9]
APG-103	DMR93WE	Inflammation	1A00-CA43.1	Investigative	[9]

Drug(s) Targeting Tumor necrosis factor receptor type I (TNF-R1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Drug 2862277	DM8WU3O	Acute lung injury	NB32.3	Phase 2	[10]
AVX-470	DMAKD0I	Inflammatory bowel disease	DD72	Phase 1	[11]
GSK1995057	DMC14KV	Adult respiratory distress syndrome	CB00	Phase 1	[12]
Anti-IFN gamma	DMXI185	Alopecia	ED70	Terminated	[11]
TNFR1 NAM	DMPTQEG	Multiple sclerosis	8A40	Investigative	[10]
NM-9405	DMKMBSJ	Rheumatoid arthritis	FA20	Investigative	[10]
TNFmab	DM4T0ZF	Rheumatoid arthritis	FA20	Investigative	[11]
ADS-0101	DMP7IS0	Chronic obstructive pulmonary disease	CA22	Investigative	[10]
Recombinant human TNF receptor	DMLYQWV	Arthritis	FA20	Investigative	[11]
TNFcept	DMAGI7K	Rheumatoid arthritis	FA20	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Apoptosis mediating surface antigen FAS (FAS)	TTF0RCZ	TNR6_HUMAN	Modulator	[4]
Tumor necrosis factor receptor type I (TNF-R1)	TTG043C	TNR1A_HUMAN	Modulator	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] VB-111 for cancer. Expert Opin Biol Ther. 2011 Dec;11(12):1669-76.
• [4] Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clin Cancer Res.2013 Jul 15;19(14):3996-4007.
• [5] ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model. BMC Musculoskeletal Disorders 2010,11:221.
• [6] Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol. 2012 May;13(1):93-100.
• [7] APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol. 2011 Feb;13(2):155-64.
• [8] Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1875).
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870).
• [11] Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
• [12] Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-alpha receptor 1. J Clin Immunol. 2013 Oct;33(7):1192-203.